Skip to main content
. 2016 Apr 14;5(7):1454–1463. doi: 10.1002/cam4.724

Figure 4.

Figure 4

Individual circulating levels of (A) bone morphogenetic proteins (BMP)‐9 and (B) soluble endoglin detected in patients at baseline and 6 h postinfusion of PF‐03446962 (day 1, cycle 1), according to treatment response. Clinical benefit includes complete or partial responses and stable disease lasting for ≥84 days.